12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Mircera 50
Roche Bangladesh Pharmaceutical
Generic: Methoxy Polyethyelene Glycol-Epoetin Beta
Medicine Overview of Mircera 50 50mcg/0.3ml Injection
বাংলা
English
Indication
Anaemia associated with chronic kidney disease
Administration
IV route is recommended for patients receiving hemodialysis because IV route may be less immunogenic
SC: inject in abdomen, arm or thigh
Adult Dose
Patients with chronic renal failure on dialysis Initiate treatment when hemoglobin level 10 g/dL, reduce or interrupt dose, and use lowest dose sufficient to reduce need for RBC transfusions Dose if not currently on ESA therapy: 0.6 mcg/kg IV/SC q2week initially Once hemoglobin has been stabilized, Mircera may be administered once monthly using a dose that is twice that of the every-two-week dose and subsequently titrated as necessary Switching Patients Currently on Other ESA Receiving epoetin 16000 units/week or darbepoetin >80 mcg/week: 360 mcg/qmonth or 180 mcg/q2week IV/SC Anemia Associated with Chronic Renal Failure Do not increase dose more frequently...
... Show moreChild Dose
Safety & efficacy not established
Contraindication
Hypersensitivity. Uncontrolled HTN.
Mode of Action
Methoxy Polyethyelene Glycol-Epoetin Beta is an erythropoietin receptor activator w/ greater activity as well as increased half-life, in contrast to erythropoietin.
Precaution
Discontinue if pure red cell aplasia. Adequate control of BP. Hemoglobinopathies, seizures, platelet level >500 x 109/L. Patients <18 yr.
Lactation: not known if excreted in breast milk, use caution
Side Effect
>10%
Hypertension (13%),Diarrhea (11%),Nasopharyngitis (11%)
1-10%
Headache (9%),Upper respiratory tract infection (9%),Cough (6%),Hypotension (5%),Urinary tract infection (5%),Procedural arteriovenous fistula thrombosis (5%)
Frequency Not Defined
Coronary artery disease,Anemia,Septic shock,Serious cardiovascular and thromboembolic events,Seizures,Immunogenicity related PRCA,Increased mortality and/or tumor progression in cancer patients,Increased mortality,Concomitant termination of other CRF therapy,Stevens-Johnson syndrome,Toxic epidermal necrolysis
Interaction
No interaction studies have been performed. There is no evidence that Mircera alters the metabolism of other medicinal products.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register